用双重和非PROTAC抑制分子向EZH2的治疗视野:最近的成就,比较分析和未来的前景
1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt.
Archiv der Pharmazie
|February 25, 2026
概括
增强ZesteHomolog 2 (EZH2) 抑制剂的增强剂正在推进癌症治疗. 本综述详细介绍了新型皮里和非皮里EZH2抑制剂,包括双杂交药物,显示了增强抗癌疗效的有希望的临床前结果.
科学领域:
- 药用化学 医学化学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 异常增强剂Zeste同类素2 (EZH2) 的过度表达驱动癌细胞的增殖和转移.
- EZH2是抗癌药物开发的验证治疗标.
- 最近的进展包括将EZH2调节与其他途径相结合的双抑制剂.
研究的目的:
- 综合审查新型EZH2抑制剂的化学多样性和合成策略.
- 分析pyridone和非pyridone支架的药理活性和结构活性关系 (SAR).
- 评估选择性和双位EZH2抑制剂的抗癌潜力.
主要方法:
- 在EZH2抑制剂开发中药物化学努力的文献综述.
- 对化合物的酶和细胞毒性活性进行比较分析.
- 对基于pyridone和非pyridone的EZH2抑制剂的SAR的评估.
主要成果:
- 像N40和136这样的化合物在淋巴瘤模型中表现出亚纳米抑制和强大的细胞毒性.
- 双目标杂交物,例如Olaparib-Tazemetostat (33),表现出协同的表观遗传和DNA修复调制.
- 在选择性和突变弹性方面取得了进展,同时在非目标效应和耐药性方面面临挑战.
结论:
- 新兴的EZH2抑制剂,特别是双目标混合体,具有显著的治疗潜力.
- 未来的战略包括合理设计,计算建模和共价功能,以提高耐用性.
- 进步为下一代EZH2抑制剂铺平了道路,超越了PROTACs.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
01:29Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
01:52Eukaryotic Transcription Inhibitors
11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K